{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:06:54Z","timestamp":1773839214071,"version":"3.50.1"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>The European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized the first European Biologic Training Course (EBTC) in Brussels on 1st March 2024. The aim of this hybrid EBTC including both face-to-face and web-based participation was to address the educational needs of physicians dealing with asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) on the clinically relevant aspects of diagnosing and treatment with biologics. EUFOREA is an international non-for-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic respiratory diseases through the implementation of optimal patient care via educational, research, and advocacy activities. The inclusive and multidisciplinary approach of EUFOREA was reflected in faculty coming from the paediatric, allergology, pulmonology, and Ear, Nose and Throat (ENT) speciality and from different continents, with more than 250 participants from over 30 countries in the first EBTC. The current report provides a comprehensive overview of key statements made by the faculty of the EBTC 2024, especially focusing on patient selection for a biologic drug, the communication with patients, the onset of biological treatment and the follow-up in routine clinical practice.<\/jats:p>","DOI":"10.3389\/falgy.2024.1517122","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T06:21:58Z","timestamp":1733984518000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["European biologic training course for type 2 inflammation by EUFOREA in 2024: key facts and lessons learned"],"prefix":"10.3389","volume":"5","author":[{"given":"D. M.","family":"Conti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Backer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Fokkens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Gevaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. K.","family":"Scadding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Bertels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Liva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Doulaptsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Prokopakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. W.","family":"Hellings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13601-017-0186-3","article-title":"European summit on the prevention and self-management of chronic respiratory diseases: report of the European union parliament summit (29 March 2017)","volume":"7","author":"Hellings","year":"2017","journal-title":"Clin Transl Allergy"},{"key":"B2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA Expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"384","DOI":"10.4193\/Rhin19.455","article-title":"Rhinology future debates 2018, a EUFOREA report","volume":"58","author":"Prokopakis","year":"2020","journal-title":"Rhinology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"298","DOI":"10.4193\/Rhin17.221","article-title":"Rhinology future debates, an EUFOREA report","volume":"55","author":"Fokkens","year":"2017","journal-title":"Rhinology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4193\/Rhin18.076","article-title":"Rhinology future trends: 2017 EUFOREA debate on allergic rhinitis","volume":"57","author":"Scadding","year":"2019","journal-title":"Rhinology"},{"key":"B6","article-title":"ULANC Northern European Masterclass","year":"2024"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/s0140-6736(00)03496-6","article-title":"Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response","volume":"356","author":"Leckie","year":"2000","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1056\/NEJMoa031261","article-title":"Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis","volume":"349","author":"Pl\u00f6tz","year":"2003","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.jaci.2023.05.014","article-title":"Safety and efficacy of dexpramipexole in eosinophilic asthma (EXHALE): a randomized controlled trial","volume":"152","author":"Siddiqui","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"E61","DOI":"10.1002\/lary.27564","article-title":"Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size","volume":"129","author":"Laidlaw","year":"2019","journal-title":"Laryngoscope"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/alr.22994","article-title":"The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps","volume":"12","author":"Gevaert","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2147\/JAA.S413064","article-title":"Tezepelumab efficacy in patients with severe, uncontrolled asthma with comorbid nasal polyps in NAVIGATOR","volume":"16","author":"Laidlaw","year":"2023","journal-title":"J Asthma Allergy"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1440868","DOI":"10.1080\/20018525.2018.1440868","article-title":"Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults","volume":"5","author":"Porsbjerg","year":"2018","journal-title":"Eur Clin Respir J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"107414","DOI":"10.1016\/j.rmed.2023.107414","article-title":"Biologics in severe asthma: a pragmatic approach for choosing the right treatment for the right patient","volume":"218","author":"Rogers","year":"2023","journal-title":"Respir Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1111\/all.13875","article-title":"EUFOREA Consensus on biologics for CRSwNP with or without asthma","volume":"74","author":"Fokkens","year":"2019","journal-title":"Allergy"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2102583","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: what is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur Respir J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4193\/Rhin22.344","article-title":"The EUFOREA pocket guide for chronic rhinosinusitis","volume":"61","author":"Hellings","year":"2023","journal-title":"Rhinology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4193\/Rhin20.601","article-title":"Executive summary of EPOS 2020 including integrated care pathways","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","article-title":"A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma","volume":"176","author":"Flood-Page","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin23.415","article-title":"EPOS2020\/EUFOREA Expert opinion on defining disease states and therapeutic goals in CRSwNP","author":"Fokkens","year":"2024","journal-title":"Rhinology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.jaip.2022.11.043","article-title":"Baseline FeNO independently predicts the dupilumab response in patients with moderate-to-severe asthma","volume":"11","author":"Pavord","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/thoraxjnl-2021-217325","article-title":"Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide","volume":"77","author":"Couillard","year":"2022","journal-title":"Thorax"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1164\/rccm.201903-0599LE","article-title":"Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a Post Hoc analysis","volume":"200","author":"Shrimanker","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/resp.14294","article-title":"Sub-stratification of type-2 high airway disease for therapeutic decision-making: a \u2018bomb\u2019 (blood eosinophils) meets \u2018magnet\u2019 (FeNO) framework","volume":"27","author":"Couillard","year":"2022","journal-title":"Respirology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"889221","DOI":"10.3389\/falgy.2022.889221","article-title":"White paper on European patient needs and suggestions on chronic type 2 inflammation of airways and skin by EUFOREA","volume":"3","author":"De Prins","year":"2022","journal-title":"Front Allergy"},{"key":"B35","doi-asserted-by":"publisher","first-page":"761388","DOI":"10.3389\/falgy.2021.761388","article-title":"Patients unmet needs in chronic rhinosinusitis with nasal polyps care: a patient advisory board statement of EUFOREA","volume":"2","author":"Claeys","year":"2021","journal-title":"Front Allergy"},{"key":"B36","doi-asserted-by":"publisher","first-page":"331","DOI":"10.4193\/Rhin19.012","article-title":"Patient advisory board for chronic rhinosinusitis\u2014a EUFOREA initiative","volume":"57","author":"Pugin","year":"2019","journal-title":"Rhinology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"107361","DOI":"10.1016\/j.rmed.2023.107361","article-title":"EUFOREA Pocket guide on the diagnosis and management of asthma: an educational and practical tool for general practitioners, non-respiratory physicians, paramedics and patients","author":"Diamant","year":"2023","journal-title":"Respir Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1048385","DOI":"10.3389\/falgy.2022.1048385","article-title":"Multiple reasons underlaying uncontrolled disease in the majority of chronic rhinosinusitis patients","volume":"3","author":"Viskens","year":"2022","journal-title":"Front Allergy"},{"key":"B39","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jaci.2019.05.019","article-title":"Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort","volume":"145","author":"Namazy","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"17607","DOI":"10.1038\/s41598-023-44973-z","article-title":"A risk of serious anaphylatic reactions to asthma biologics: a pharmacovigilance study based on a global real-world database","volume":"13","author":"Park","year":"2023","journal-title":"Sci Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jaci.2014.02.007","article-title":"Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab","volume":"134","author":"Long","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"100737","DOI":"10.1016\/j.waojou.2022.100737","article-title":"Risks and safety of biologics: a practical guide for allergists","volume":"16","author":"Sitek","year":"2023","journal-title":"World Allergy Organ J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin22.489","article-title":"EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023","author":"Fokkens","year":"2023","journal-title":"Rhinology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e12038","DOI":"10.1002\/clt2.12038","article-title":"Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab","volume":"11","author":"Li","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.12.312","article-title":"The xolair pregnancy registry (EXPECT): an observational study of the safety of omalizumab during pregnancy in women with asthma","author":"Namazy","year":"2019","journal-title":"JACI"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1276340","DOI":"10.3389\/fphar.2023.1276340","article-title":"Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration\u2019s adverse event reporting system (FAERS)","volume":"14","author":"Pera","year":"2023","journal-title":"Front Pharmacol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jacig.2021.12.003","article-title":"Preclinical and clinical experience with dupilumab on the correlates of live attenuated vaccines","volume":"1","author":"Wechsler","year":"2021","journal-title":"J Allergy Clin Immunol Glob"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1291185","DOI":"10.3389\/falgy.2023.1291185","article-title":"Pre-asthma: a useful concept for prevention and disease-modification? A EUFOREA paper. Part 1\u2014allergic asthma","volume":"4","author":"Scadding","year":"2021","journal-title":"Front Allergy"},{"key":"B49","doi-asserted-by":"publisher","first-page":"706589","DOI":"10.3389\/falgy.2021.706589","article-title":"Allergic rhinitis in childhood and the new EUFOREA algorithm","volume":"2","author":"Scadding","year":"2021","journal-title":"Front Allergy"},{"key":"B50","doi-asserted-by":"publisher","first-page":"618","DOI":"10.4193\/Rhin20.246","article-title":"EUFOREA Treatment algorithm for allergic rhinitis","volume":"58","author":"Hellings","year":"2020","journal-title":"Rhinology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1240375","DOI":"10.3389\/falgy.2023.1240375","article-title":"Bringing the treatable traits approach to primary care asthma management","volume":"4","author":"Pfeffer","year":"2023","journal-title":"Front Allergy"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Pavord ID; SIRIUS investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"ZONDA trial investigators. Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1164\/rccm.201412-2278OC","article-title":"Cytokines in chronic rhinosinusitis. Role in eosinophilia and aspirin-exacerbated respiratory disease","volume":"192","author":"Stevens","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.jaci.2013.01.043","article-title":"Chronic rhinosinusitis with nasal polyps is characterized by B-cell inflammation and EBV-induced protein 2 expression","volume":"131","author":"Hulse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","article-title":"Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study","volume":"403","author":"Jackson","year":"2024","journal-title":"Lancet"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2100396","DOI":"10.1183\/13993003.00396-2021","article-title":"Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)","volume":"59","author":"Moore","year":"2022","journal-title":"Eur Respir J"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jaip.2020.10.035","article-title":"The relationship of asthma biologics to remission for asthma","volume":"9","author":"Menzies-Gow","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2300819","DOI":"10.1183\/13993003.00819-2023","article-title":"UK severe asthma registry. Clinical remission in severe asthma with biologic therapy: an analysis from the UK severe asthma registry","volume":"62","author":"McDowell","year":"2023","journal-title":"Eur Respir J"},{"key":"B64","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/rheumatology\/kex528","article-title":"The relationship between depression and biologic treatment response in rheumatoid arthritis: an analysis of the British society for rheumatology biologics register","volume":"57","author":"Matcham","year":"2018","journal-title":"Rheumatology"},{"key":"B65","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1186\/s12890-022-02241-2","article-title":"Life-changing\": the experience of super-responders to biologics in severe asthma","volume":"22","author":"Lanario","year":"2022","journal-title":"BMC Pulm Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.jaci.2018.12.986","article-title":"Prevalence of chronic rhinosinusitis in the general population based on sinus radiology and symptomatology","volume":"143","author":"de Loos D","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1002\/lary.20653","article-title":"Long-term outcomes from the English national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis","volume":"119","author":"Hopkins","year":"2009","journal-title":"Laryngoscope"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/all.15982","article-title":"EUFOREA\/EPOS2020 statement on the clinical considerations for CRSwNP care","author":"Hellings","year":"2023","journal-title":"Allergy"},{"key":"B69","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13601-019-0269-4","article-title":"Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis","volume":"9","author":"Calus","year":"2019","journal-title":"Clin Transl Allergy"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/alr.23044","article-title":"Indications for absorbable steroid-eluting sinus implants: viewpoint via the delphi method","volume":"12","author":"Lee","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1111\/all.15772","article-title":"Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational Phase IV real-life study (DUPIREAL)","volume":"78","author":"De Corso","year":"2023","journal-title":"Allergy"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1111\/all.15796","article-title":"Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months","volume":"78","author":"van der Lans","year":"2023","journal-title":"Allergy"},{"key":"B73","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1042\/CS20190281","article-title":"New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis","volume":"137","author":"Striz","year":"2023","journal-title":"Clin Sci"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s40265-021-01597-9","article-title":"REal worlD effectiveness and safety of mepolizumab in a multicentric spanish cohort of asthma patients stratified by eosinophils: the REDES study","volume":"81","author":"Domingo Ribas","year":"2021","journal-title":"Drugs"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1372919","DOI":"10.3389\/falgy.2024.1372919","article-title":"Nasal polyp syndrome: a patient-centred term for CRSwNP by EUFOREA","volume":"5","author":"Theeling","year":"2024","journal-title":"Front Allergy"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2024.1517122\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T06:22:02Z","timestamp":1733984522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2024.1517122\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":75,"alternative-id":["10.3389\/falgy.2024.1517122"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2024.1517122","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]},"article-number":"1517122"}}